Navigation Links
MHA Announces Release of RxPertise(TM) 8.0
Date:9/16/2009

FLORHAM PARK, N.J., Sept. 16 /PRNewswire/ -- Managed Health Care Associates, Inc. (MHA), the largest Alternate Site Group Purchasing Organization (GPO) in the country, today announced the immediate availability of RxPertise Consulting Software, Version 8.0. RxPertise is a leading Medication Regimen Review (MRR) software for consultant pharmacists in the Long Term Care industry. The software enables users to efficiently manage the utilization, outcomes, and reporting requirements for patients in skilled nursing, assisted living and extended care facilities.

"With our latest version 8.0 MHA continues to standout in the market by improving upon an already highly valued service offering," commented Lou Livolsi, Senior Vice President, Long Term Care for MHA. "RxPertise is one of the many critical support services offered by MHA that our Long Term Care members rely on to drive their business success."

Jay Loeper, Pharm.D. FASCP, RxPertise Product Manager and Director, Clinical Software Development for MHA added, "RxPertise 8.0 offers a new flexible user-interface, reporting customizations, and aggregate reporting capabilities that are testament to MHA listening to what our clients want, and delivering it. This revision showcases benefits to the consultant pharmacists as well as their customers."

RxPertise 8.0 provides powerful reporting and graphing enhancements, and offers an improved work environment and database structure. Additional enhancements include:

  • A user's ability to customize the look and feel of RxPertise.
  • Report enhancements including company logo and pharmacist's digital signature support.
  • Aggregate Reporting/graphics providing capability to compare statistical data across groups of care centers.
  • Supports 64-bit Windows operating systems.

For more information on this
'/>"/>

SOURCE Managed Health Care Associates, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. CSL Biotherapies Announces FDA Marketing Approval of its Monovalent Pandemic (H1N1) 2009 Influenza A Vaccine
2. FindFloridaLawyer.com Announces the Grand Opening of Its Online Attorney Search and Legal Resource Site
3. Telik Announces Presentation and Webcast at UBS Global Life Sciences Conference
4. Cowen Announces Hiring of Don Munoz to Lead Medical Technology Practice; 5th Senior-Level Addition to Cowens Health Care Franchise in 2009
5. Metametrix Announces Availability of Phthalates & Parabens Profile to Help Identify Everyday Exposures
6. Post Acute Medical / Warm Springs Announces Long-Term Contractual Relationship With Gulf States LTAC of New Braunfels
7. ASAP Systems Announces Additional Changes to its Inventory, Warehouse, Stock Tracking, Capital and Fixed Assets Management System and Reseller Program
8. Sono-Tek Announces its Largest Ever Sales of MediCoat Stent Coating Systems to a Leading Global Medical Device Manufacturer
9. Nuvilex, Inc. Announces That Reme-Flu(TM) Will Be Available For Sale On Top-Rated Internet Website
10. Global Med Technologies(R), Inc. Announces Its First EdgeCell Cellular Therapy Software and EdgeLab/HLA Software Sale in North America
11. Accumetrics, Inc. Announces Endotech SPA as Exclusive Distributor for the VerifyNow System in Italy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... Bronx, NY (PRWEB) , ... September 01, 2015 , ... ... for 86 children and teenagers, from ages 6-18. Calvary’s Camp Compass® has taken place ... camp staff included 65 adult counselors, some of whom work for Calvary, and two ...
(Date:9/1/2015)... ... September 01, 2015 , ... Consumers overwhelmingly prefer to have ... Surgery, according to a new survey that also offers insight on why that ... – which reflects views on cosmetic medical treatments and ratings for 10 specific ...
(Date:9/1/2015)... ... September 01, 2015 , ... Plaza OBGYN in ... MonaLisa Touch® , an innovative vaginal health laser procedure that prevents and resolves ... treatment for atrophic vaginitis, a condition that causes vaginal dryness, pelvic discomfort, painful ...
(Date:9/1/2015)... ... September 01, 2015 , ... With former IBMers among its ... disciplines since its inception more than 35 years ago. A pilot program begun by ... teachers - and, not just those intent on pursuing careers in these fields. The ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... Nelson, D.O., has joined its medical management team as an Associate Medical Director. ... all sizes and types in the U.S. and abroad. , Dr. Nelson ...
Breaking Medicine News(10 mins):Health News:Calvary Hospital Hosts 18th Annual Bereavement Camp 2Health News:Calvary Hospital Hosts 18th Annual Bereavement Camp 3Health News:Survey: Consumers Prefer ASDS Members 2Health News:Survey: Consumers Prefer ASDS Members 3Health News:Houston's Plaza OB/GYN Now Offering the MonaLisa Touch® 2Health News:Houston's Plaza OB/GYN Now Offering the MonaLisa Touch® 3Health News:Inmar Announces Program to Fuel Student Passion for STEM – with an Unconventional Twist 2Health News:Dr. Brent Nelson Joins WorkCare, Inc., as Associate Medical Director 2Health News:Dr. Brent Nelson Joins WorkCare, Inc., as Associate Medical Director 3
... (LTR) at the LSU Health Sciences Center New Orleans ... million contract over seven years by the National Cancer ... Epidemiology and End Results) Program-designated cancer registry. There are ... States., "The SEER Program is the most authoritative source ...
... if therapeutic anticancer vaccines, which are designed to boost ... developed. For example, the viruses used to deliver the ... targeted by the patient,s immune system, inducing neutralizing and ... by Michael Morse, at Duke University Medical Center, Durham, ...
... By Amanda Gardner HealthDay Reporter , MONDAY, Aug. ... to fashion a therapeutic vaccine that appears to attack a ... required tumor-fighting immune response in early human trials, but only ... urged caution. "They were able to generate an immune ...
... N.C., Aug. 2 - Merz Pharmaceuticals today announced that ... has approved Xeomin (incobotulinumtoxinA), a botulinum toxin type ... or blepharospasm. According to an epidemiology study conducted in ... cervical dystonia and blepharospasm, is estimated at 295 per ...
... able to significantly reduce the radiation dose associated with ... one day dose optimization workshop provided by the Royal ... supported by the local state health department, according to ... Journal of the American College of Radiology (www.jacr.org). ...
... A study in the Aug. 1 issue of the journal ... age male infants are easier to arouse than females during quiet ... no significant gender differences in arousability. The results suggest that ... may not reflect a pre-existing vulnerability involving arousal responses. Results ...
Cached Medicine News:Health News:LA Tumor Registry at LSUHSC awarded $12 million SEER contract by NCI 2Health News:LA Tumor Registry at LSUHSC awarded $12 million SEER contract by NCI 3Health News:Vaccine Shows Some Promise Against Advanced Cancers 2Health News:FDA approves Merz Pharmaceuticals' Xeomin (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm 2Health News:FDA approves Merz Pharmaceuticals' Xeomin (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm 3Health News:FDA approves Merz Pharmaceuticals' Xeomin (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm 4Health News:SIDS surprise: Study finds that infant boys are more easily aroused from sleep than girls 2Health News:SIDS surprise: Study finds that infant boys are more easily aroused from sleep than girls 3
(Date:9/1/2015)... SPRINGDALE, Ark. , Sept. 1, 2015 NOWDiagnostics Inc., ... completed its acquisition of ZBx Corporation of Canada ... to its vision of a world where people have ... NOWDiagnostics manufactures and sells a line of unique blood-based ... simple-to-use, highly accurate tests for a variety of ailments ...
(Date:9/1/2015)... 1, 2015 UT Southwestern Medical Center President ... members joined U.S. Representatives Michael C. Burgess , ... discussion on the 21 st Century Cures Act, ... considered by the United States ... Academy of Sciences members, department chairs, center directors, and ...
(Date:9/1/2015)... Sept. 1, 2015  Results from an interim analysis ... that 5g of idarucizumab enabled emergency surgery to ... treated with dabigatran (Pradaxa ® dabigatran etexilate ... effect of dabigatran enabled patients to be urgently ... of 1.7 hours between administration of idarucizumab and ...
Breaking Medicine Technology:NOWDiagnostics Inc. Acquires Canada's ZBx Corporation 2NOWDiagnostics Inc. Acquires Canada's ZBx Corporation 3U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 2U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 3U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 4U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 5New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 2New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 3New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 4New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 5New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 6New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 7New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 8New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 9
... in wake of AHA-presented data , ... a clinical trial suggesting rosuvastatin may lower the cardiovascular risk ... statin use in older adults, according to a national poll ... the online poll conducted by medical news site MedPage Today ...
... FRANCISCO, Calif., Nov. 25 Poniard,Pharmaceuticals, Inc. (Nasdaq: ... on,innovative oncology therapies, announced today that it will ... in order to allow,the Company to focus its ... product candidate, and to support the initial commercialization ...
Cached Medicine Technology:Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 2Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 3Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin 2Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin 3
... Right Solution For Your Tracheostomy Care Needs, ... tray features the latest components for efficient ... control task. Designed by clinicians, these latex-free ... each patient and caregiver. All of our ...
... Right Solution For Your Tracheostomy Care Needs, ... tray features the latest components for efficient ... control task. Designed by clinicians, these latex-free ... each patient and caregiver. All of our ...
... alternate care facilities with a wide ... offer the finest in nursing convenience ... guidance of experienced nursing personnel, these ... is required for efficient and quick ...
... alternate care facilities with a wide ... offer the finest in nursing convenience ... guidance of experienced nursing personnel, these ... is required for efficient and quick ...
Medicine Products: